Endometriose

Zusammenfassung Endometriose ist ein häufiger Grund für unerfüllten Kinderwunsch und chronische Schmerzen. Die Erforschung neuer Therapiekonzepte dient in erster Linie der Verbesserung der Lebensqualität. Es ist denkbar, dass neue, spezifisch wirksame Substanzen auf der Basis molekularbiologischer Forschung in Zukunft dem Therapieziel der Heilung zumindest nahe kommen. Der klassische Weg der Therapie wird bisher häufig kombiniert operativ und medikamentös beschritten. Die Hemmung der Östradiolsynthese galt bislang als wichtigste Therapieoption. Mit selektiven Östradiolrezeptormodulatoren kann zudem die Wirkung des Östradiols deutlich gehemmt werden. Auch selektive Progesteronrezeptormodulatoren sind bei hoher Spezifität antiproliferativ wirksam. Mit der Hemmung von Matrixmetalloproteinasen wird die Implantation endometrioider Herde verhindert. Die Ausbildung neuer Gefäße, die die Proliferation ermöglichen, wird möglicherweise durch antiangiogenetisch wirksame Substanzen verhindert. Eine Hemmung der Synthese und Sekretion von Zytokinen wird mit Hilfe von antiinflammatorischen Substanzen, Antikörpern oder Bindungsproteinen angestrebt. Abstract Endometriosis is a common cause for infertility and chronic pain. Investigations for new therapeutic concepts are mainly aimed to achieve better life quality. New specific substances, based on molecular biological investigations, may be helpful to approach the goal of healing patients. The most common therapeutic concept is to combine operative treatment with drug therapy. The main therapeutic option today is to inhibit the estradiol biosynthesis. In addition, selective estradiol receptor modulators may inhibit the effects of estradiol. Also, selective progesterone receptor modulators are acting specifically against the proliferating potential of endometriosis. While inhibiting matrix metalloproteinases, the implantation of endometriotic tissue can be blocked. Sprouting of new vessels, which provides the potential of proliferation, could possibly be blocked by antiangiogenic substances. Using anti-inflammatory drugs, antibodies or binding proteins, the synthesis and secretion of cytokines could be inhibited. Similar content being viewed by others Literatur Bulun SE, Zeitoun KM, Takayama K, Simpson E, Sasano H (2000) Aromatase as a therapeutic target in endometriosis. Trends Endocrinol Metab 11: 22–27 Chwalisz K (2003) New selective progesterone receptor modulators (SPRMs) in the treatment of endometriosis. 19th ESHRE Annual Meeting 87–88 Dabrosin C, Gyorffy S, Margetts P, Ross C and Gauldie J (2002) Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 161: 909–918 D’Hooghe TM (2003) Immunomodulators and aromatase inhibitors: are they the next generation of treatment for endometriosis? Curr Opin Obstet Gynecol 15: 243–249 D’Hooghe TM, Cuneo S, Nugent N, Chai D, Deer F and Mwenda J (2001) Recombinant human TNF binding protein-1 (r-hTBP-1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 76: S1 Evans A, Vollenhoven B, Healy D (1999) Modern antioestrogens and the coming revolution in women’s health care. Aust N Z J Obstet Gynaecol 39: 334–340 Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA (2000) Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 95: 3490–3497 Fedele L, Bianchi S, Zanconato G, Portuese A, Raffaelli R (2001) Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 75: 485–488 Gazvani R, Templeton A (2002) Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 123: 217–226 Giudice LC (2003) Genomics‘ role in understanding the pathogenesis of endometriosis. Semin Reprod Med 21: 119–124 Hornung D, Ryan IP, Chao VA, Vigne JL, Schriock ED, Taylor RN (1997) Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J Clin Endocrinol Metab 82: 1621–1628 Hull ML, Charnock-Jones DS, Chan CL et al. (2003) Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 88: 2889–2899 Kao LC, Germeyer A, Tulac S et al. (2003) Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology 144: 2870–2881 Kayisli UA, Mahutte NG, Arici A (2002) Uterine chemokines in reproductive physiology and pathology. Am J Reprod Immunol 47: 213–221 Koninckx PR, Kennedy SH, Barlow DH (1998) Endometriotic disease: the role of peritoneal fluid. Hum Reprod Update 4: 741–751 Küpker W, Felberbaum R, Bauer O, Diedrich K (1996) Significance of tumor necrosis factor alpha (TNF-alpha) in endometriosis. Geburtshilfe Frauenheilkd 56: 239–242 Küpker W, Schultze-Mosgau A, Diedrich K (1998) Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update 4: 719–723 Lau TM, Affandi B, Rogers PA (1999) The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium. Mol Hum Reprod 5: 57–63 Mori T, Yamasaki S, Masui F, Matsuda M, Sasabe H, Zhou YF (2001) Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med (Maywood) 226: 429–433 Noble LS, Takayama K, Zeitoun KM et al. (1997) Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 82: 600–606 Olive DL (2003) Medical therapy of endometriosis. Semin Reprod Med 21: 209–222 Ramey JW, Archer DF (1993) Peritoneal fluid: its relevance to the development of endometriosis. Fertil Steril 60: 1–14 Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR and Bulun SE (1998) Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 69: 709–713 Taylor RN, Lebovic DI, Mueller MD (2002) Angiogenic factors in endometriosis. Ann N Y Acad Sci 955: 89–100 Wu MY, Ho HN (2003) The role of cytokines in endometriosis. Am J Reprod Immunol 49: 285–296 Zeitoun K, Takayama K, Michael MD, Bulun SE (1999) Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. Mol Endocrinol 13: 239–253 Zeitoun KM, Bulun SE (1999) Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 72: 961–969 Interessenkonflikt: Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Finas, D., Friedrich, M., Diesing, D. et al. Endometriose. Gynäkologe 37, 116–122 (2004). https://doi.org/10.1007/s00129-003-1478-3 Issue date: DOI: https://doi.org/10.1007/s00129-003-1478-3